Related Experiment Video

Updated: Jun 13, 2026

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
07:28

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

Alzheimer's Disease Beyond Abeta

Terrence Town1

  • 1Department of Biomedical Sciences, Regenerative Medicine Institute, Cedars-Sinai Medical Center, SSB3 Room 361, Los Angeles, CA 90048, USA. terrence.town@cshs.org

Expert Review of Neurotherapeutics
|May 1, 2010
PubMed

Insights

Alzheimer's disease (AD) trials targeting amyloid-beta peptide (Abeta) show a multifocal approach is needed. Future AD therapeutics beyond Abeta require critical discussion and new targets for effective intervention.

Area of Science:

  • Neuroscience
  • Neurology
  • Biochemistry

Background:

  • Alzheimer's disease (AD) clinical trials targeting amyloid-beta peptide (Abeta) are yielding conclusions.
  • A multifocal therapeutic strategy is increasingly recognized as necessary for AD treatment.
  • Discussion beyond Abeta is crucial for identifying next-generation AD therapeutic targets.

Purpose of the Study:

  • To report highlights from the 2010 Keystone Symposium, 'Alzheimer's Disease Beyond Abeta'.
  • To discuss emerging evidence and spark debate on AD therapeutics beyond Abeta.
  • To identify key questions for future AD research and therapeutic development.

Main Methods:

  • Summary of presentations and discussions from the Keystone Symposium.
  • Review of scientific evidence presented at the meeting.
  • Analysis of ongoing debates regarding AD biomarkers and therapeutic targets.

Main Results:

  • New evidence suggests potential next-generation therapeutic targets beyond Abeta.
  • Discussions highlighted the complexity of AD and the need for diverse approaches.
  • The symposium facilitated awareness of emerging research directions in AD therapeutics.

Conclusions:

  • A multifocal approach is essential for effective Alzheimer's disease treatment.
  • Further research is needed to identify optimal biomarkers and therapeutic targets beyond Abeta.
  • Critical discussions are necessary to advance the development of novel AD interventions.

More Related Videos

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons06:23

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.